Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera
Cancer Research and Treatment · 15.07.2026 · 58 (3) · 954-962
DOI: 10.4143/crt.2025.552 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Research and Treatment, erschienen am 15.07.2026. Verfasst von Ji Yun Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: Polycythemia Vera, Polyethylene Glycols, Interferon alpha-2, Interferon-alpha. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: PharmaEssentia Corporation.
Abstract (Originalsprache)
Purpose
Conventional management of low-risk polycythemia vera (PV), consisting of phlebotomy and aspirin, often fails to adequately control symptoms and hematologic parameters. This study evaluated the efficacy and safety of ropeginterferon alfa-2b (Ropeg) in low-risk PV patients requiring cytoreductive therapy.Materials and Methods In this sub-analysis of an open-label, multicenter trial, 42 patients received Ropeg for 48 weeks. The primary endpoint was a reduction in phlebotomy frequency, while secondary endpoints included complete hematologic response (CHR), changes in JAK2V617F allele burden, and safety.
Results
Among 42 patients, Ropeg significantly reduced mean phlebotomy frequency per year from 3.0 to 0.5 (p < 0.05) and improved CHR rates (69.1% at 48 weeks). The JAK2V617F allele burden decreased, and hydroxyurea-naïve patients showed better responses. The most frequently reported treatment-related adverse events included elevated liver enzymes and alopecia. Most adverse events were mild or moderate, with no grade 4 or 5 events reported.
Conclusion
These findings suggest that Ropeg is a promising treatment option for low-risk PV by effectively reducing the need for phlebotomy and demonstrating efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
- Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea.
- Division of Hematology & Medical Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
- Division of Hematology-Oncology, Department of Internal Medicine, Institute of Health Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.
Förderung
- PharmaEssentia Corporation
Zitieren
APA
Lee, J. Y., Yoon, S. S., Yang, D. H., Sohn, S. K., Yoon, S. Y., Bang, S. M., Lee, G. W., Choi, C. W., Choi, E. J., Cheong, J. W., Park, Y. H., & Lee, S. E. (2026). Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera. Cancer Research and Treatment, 58(3), 954-962. https://doi.org/10.4143/crt.2025.552
Vancouver
Lee JY, Yoon SS, Yang DH, Sohn SK, Yoon SY, Bang SM, et al. Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera. Cancer Research and Treatment. 2026;58(3):954-962. doi:10.4143/crt.2025.552
BibTeX
@article{Lee2026,
author = {Lee, Ji Yun and Yoon, Sung-Soo and Yang, Deok-Hwan and Sohn, Sang Kyun and Yoon, Seug Yun and Bang, Soo-Mee and Lee, Gyeong-Won and Choi, Chul Won and Choi, Eun-Ji and Cheong, June-Won and Park, Young Hoon and Lee, Sung-Eun},
title = {Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera},
journal = {Cancer Research and Treatment},
year = {2026},
volume = {58},
number = {3},
pages = {954--962},
doi = {10.4143/crt.2025.552}
}
EUVIMED